Inter-ethnic differences in xenobiotic metabolism

Environmental Toxicology and Pharmacology

Volumn 2, Issue 2-3, 1996, Pages 165-170

  Renwick, Andrew G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cytochrome P450; Drug metabolism; Ethnic difference; Pharmacogenetics; Polymorphism

Indexed keywords

CYTOCHROME P450;

CONFERENCE PAPER; DRUG METABOLISM; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; HUMAN; OXIDATION; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; XENOBIOTIC METABOLISM;

EID: 0030588203     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1382-6689(96)00049-X     Document Type: Conference Paper

References (53)

1. Aarons, L., 1996, Population approaches/sparse data analysis for human variability in kinetics and dynamics, Environ. Toxicol. Pharmacol. 2, 197-199.
2. Agarwal, D.P. and H.W. Goedde, 1992, Pharmacogenetics of alcohol dehydrogenase, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 263-280.
3. Ahsan, C.H., A.G. Renwick, B. Macklin, V.F. Challenor, D.G. Waller and C.F. George, 1991, Ethnic differences in the pharmacokinetics of oral nifedipine, Br. J. Clin. Pharmacol. 31, 399-403.
4. Ahsan, C.H., A.G. Renwick, D.G. Waller, V.F. Challenor, C.F. George and M. Amanullah, 1993, The influence of dose and ethnic origins on the pharmacokinetics of nifedipine, Clin. Pharmacol. Ther. 54, 329-338.
5. Boobis, A.R., D.J. Fawthrop, C.E. Seddon, C.J. Speirs and D.S. Davies, 1992, Variability in the pharmacokinetics and metabolism of acetaminophen, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 791-812.
6. Castaneda-Hernández, G., C. Hoyo-Vadillo, J.A. Palma-Aquirre and F.J. Flores-Murrieta, 1992, Pharmacokinetics of oral nifedipine in different populations, J. Clin. Pharmacol. 32, 140-145.
7. Cosma, G., P. Toniolo, D. Currie, B. Pasternack and S. Garte, 1992, Expression of the CYP1A1 gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers. Cancer Epidemiol. Biomarker Prevent. 1, 137-142.
8. Cosma, G., F. Crofts, E. Taioli, P. Toniolo and S. Garte, 1993, Relationship between genotype and function of the human CYP1A1 gene, J. Toxicol. Environ. Health 40, 309-316.
9. Critchley, J.A.J.H., G.R. Nimmo, C.A. Gregson, N.M. Woolhouse and L.F. Prescott, 1986, Inter-subject and ethnic differences in paracetamol metabolism, Br. J. Clin. Pharmacol. 22, 649-657.
10. Doshi, B.S., R.D. Kulkarni, B.L. Chauhan and G.R. Wilkinson, 1990, Frequency of impaired mephenytoin 4′-hydroxylation in an Indian population, Br. J. Clin. Pharmacol. 30, 779-780.
11. Eichelbaum, M. and A.S. Gross, 1992, The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow, (Pergamon Press, New York) pp. 625-648.
12. Evans, W.E., M.V. Relling, A. Rahman, H.L. McLeod, E.P. Scott and J-S. Lin, 1993, Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans, J. Clin. Invest. 91, 2150-2154.
13. Goedde, H.W. and D.P. Agarwal, 1992, Pharmacogenetics of aldehyde dehydrogenase, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 281 -311.
14. Gonzalez, F.J., 1992, Molecular genetics of the P-450 superfamily, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 413-452.
15. Horai, Y., M. Nakano, T. Ishizaki, K. Ishikawa, H.-H. Zhou, B.-J. Zhou, C.-L. Liao and L.-M. Zhang, 1989, Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese, Clin. Pharmacol. Ther. 46, 198-207.
16. Ingelman-Sundberg, M., I. Johansson, I. Persson, Q.-Y. Yue, M.L. Dahl, L. Bertilsson and F. Sjöqvist, 1992, Genetic polymorphism of cytochrome P450: interethnic differences and relationship to incidence of lung cancer, Pharmacogenetics 2, 264-271.
17. Jameson, J.P. and A. Munyika, 1990, Theophylline pharmacokinetics in black Zimbabwean males, Ther. Drug Monit. 12, 54-58.
18. Jurima, M., T. Inaba, D. Kadar and W. Kalow, 1985, Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians, Br. J. Clin. Pharmacol. 19, 483-487.
19. Kalow, W., 1991, Interethnic variation in drug metabolism, Trends Pharmacol. Sci. 12, 102-107.
20. Ketterer, B., 1996, Effects of genetic polymorphism and enzyme induction in the glutathione-S-transferase family on chemical safety and risk assessment, Environ. Toxicol. Pharmacol. 2, 157-160.
21. Kinirons, M.T., C.C. Lang, H.B. Huai, K. Ghebreselasie, S. Shay, D.W. Robin and A.J.J. Wood, 1996, Triazolam pharmacokinetics and pharmacodynamics in Caucasians and South Asians: ethnicity and CYP3A activity, Br. J. Clin. Pharmacol. 41, 69-72.
22. LaDu, B.N., 1992, Human serum paroxonase/arylesterase, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 51-91.
23. Lee, E.J.D. and W. Kalow, 1993, Thiopurine S-methyltransferase activity in a Chinese population, Clin. Pharmacol. Ther. 54, 28-33.
24. Lennard, M.S., A.O. Iyun, P.R. Jackson, G.T. Tucker and H.F. Woods, 1992, Evidence for a dissociation of sparteine, debrisoquine and metoprolol in Nigerians, Pharmacogenetics 2, 89-92.
25. Lin, K.-M., R.E. Poland, J.K. Lau and R.T. Rubin, 1988. Haloperidol and prolactin concentrations in Asians and Caucasians, J. Clin. Psychopharmacol. 8, 195-201.
26. Lindholm, A., M. Welsh, C. Alton and B.D. Kahan, 1992, Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability, Clin. Pharmacol. Ther. 52, 359-371.
27. Lockridge, O., 1992, Genetic variants of human serum butyrylcholinesterase influence the metabolism of the muscle relaxant succinylcholine, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York) pp. 15-50.
28. Mathan, V.I., J. Wiederman, J.F, Dobkin and J. Lindenbaum, 1989, Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora, Gut 30, 971-977.
29. McLeod, H.L., J.-S. Lin, E.P. Scott, C.-H. Pui and W.E. Evans, 1994, Thiopurine methyltransferase activity in American white subjects and black subjects, Clin. Pharmacol. Ther. 55, 15-20.
30. Miners, J.O. and P.I. Mackenzie, 1991, Drug glucuronidation in humans, Pharmacol. Ther. 51, 347-369.
31. Nakamura, K., F, Goto, W.A. Ray, C.B. McAllister, E. Jacqz, G.R. Wilkinson and R.A. Branch, 1985, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin. Pharm. Ther. 38, 402-408.
32. Playfer, J.R., L.C. Eze, M.F. Bullen and D.A.P. Evans, 1976, Genetic polymorphism and inter ethnic variability in paraoxonase activity, J. Med. Genet. 13, 337-342.
33. Price Evans, D.A. 1992, N-Acetyltransferase, in: Pharmacogenetics of Drug Metabolism. ed. W. Kalow (Pergamon Press, New York) pp. 95-178.
34. Rashid, T.J., U. Martin, H. Clarke, D.G. Waller, A.G. Renwick and C.F. George, 1995, Factors affecting the absolute bioavailability of nifedipine, Br. J. Clin. Pharmacol. 40, 51-58.
35. Relling, M.V., J-S. Lin, G.D. Ayers and W.E. Evans, 1992, Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities, Clin. Pharmacol. Ther. 52, 643-658.
36. Renwick, A.G., 1993, Data-derived safety factors for the evaluation of food additives and environmental contaminants, Food Addit. Contamin. 10, 275-305.
37. Roots, I., N. Drakoulis and J. Brockmöller, 1992, Polymorphism enzymes and cancer risk: concepts, methodology and data review, in: Pharmacogenetics of Drug Metabolism. ed. W. Kalow (Pergamon Press, New York) pp. 815-841.
38. Rutledge, D.R., L. Cardozo and J.D. Steinberg. 1989, Racial differences in drug response: isoproterenol effects on heart rate in healthy males, Pharm. Res. 6, 182-185.
39. Satariono, W.A. and G.M. Swanson, 1988, Racial differences in cancer incidence: the significance of age-specific patterns, Cancer 62, 2640-2653.
40. Shields, P.G., N.E. Caporaso, R.T. Falk, H. Sugimura, G.E. Trivers, B.F. Trump, R.N. Hoover, A. Weston and C.C. Harris, 1993, Lung cancer, race and a CYP1A1 genetic polymorphism, Cancer Epidemiol. Biomarker Prevent. 2, 481-485.
41. Sommers, D.K., J. Moncrieff and J. Avenant, 1989, Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda, Hum. Toxicol, 8, 365-368.
42. Soons, P.A., J.H.M. Schellens and D.D. Breimer, 1992, Variability in pharmacokinetics and metabolism of nifedipine and other dihydropyridine calcium entry blockers, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow. (Pergamon Press, New York), pp. 769-789.
43. Sowunmi, A., J. Rashid, O.O. Akinyinka and A.G. Renwick, 1995, Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians, Br. J. Clin. Pharmacol. 40, 489-493.
44. 1-adrenoceptor responses in normotensive Caucasians and West Africans, Br. J. Clin. Pharmacol. 21, 401-408.
45. Wagenknecht, L.E., G.R. Cutter, N.J. Haley, S. Sidney, T.A. Manolio, G.H. Hughes and D.R. Jacobs, 1990, Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study, Am. J. Public Health 80, 1053-1056.
46. Weinshilboum, R., 1992, Sulfotransferase pharmacognetics, in: Pharmacogenetics of Drug Metabolism, ed. W. Kalow (Pergamon Press, New York), pp. 227-242.
47. Wilkinson, G.R., F.P. Guengerich and R.A. Branch, 1992, Genetic polymorphism of S-mephenytoin hydroxylation, in: Pharmacogentics of Drug Metabolism, ed. W. Kalow, (Pergamon Press, New York) pp. 657-685.
48. Williams, F.M., E.N. Nicholson, N.W. Woolhouse, K.K. Adjepon-Yamoah and M.D. Rawlins, 1986, Activity of esterases in plasma from Ghanaian and British subjects, Eur, J. Clin. Pharmacol. 31, 485-489.
49. Wood, A.J.J. and H.H. Zhou, 1991, Ethnic differences in drug disposition and responsiveness, Clin. Pharmacokinet, 20, 350-373.
50. Woolhouse, N.M., M. Eichelbaum, N.S. Oates, J.R. Idle and R.L. Smith, 1985, Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians, Clin. Pharmacol. Ther. 37, 512-521.
51. Yu, M.C., P.L. Skipper, K. Taghizadeh, S.R. Tannenbaum, K.K. Chan, B.E. Henderson and R.K. Ross, 1994, Acetylator phenotype, amino-biphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black and Asian men in Los Angeles, California. J. Natl. Cancer Inst. 86, 712-716.
52. Zhou, H.-H., R.P. Koshakji, D.J. Silberstein, G.R. Wilkinson and A.J.J. Wood, 1989, Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites, New Engl. J. Med. 320, 565-570.
53. Zhou, H.H., J.R. Sheller, H. Nu, M. Wood and A.J.J. Wood, 1993, Ethnic differences in response to morphine, Clin. Pharmacol. Ther. 54, 507-513.